Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

1.1%

7 terminated/withdrawn out of 619 trials

Success Rate

93.0%

+6.5% vs industry average

Late-Stage Pipeline

11%

67 trials in Phase 3/4

Results Transparency

2%

2 of 93 completed trials have results

Key Signals

174 recruiting2 with results

Enrollment Performance

Analytics

Phase 2
148(39.3%)
N/A
129(34.2%)
Phase 3
45(11.9%)
Phase 1
28(7.4%)
Phase 4
22(5.8%)
Early Phase 1
5(1.3%)
377Total
Phase 2(148)
N/A(129)
Phase 3(45)
Phase 1(28)
+2 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (619)

Showing 20 of 619 trials
NCT07645846Phase 2Not Yet Recruiting

Neoadjuvant Docetaxel, Cisplatin, and Dual Immunotherapy for Sinonasal Carcinoma

Role: collaborator

NCT05787509Phase 4Recruiting

Prolonged Progesterone to Prevent Preterm Birth From IVF - ET

Role: lead

NCT07636096Completed

Breast Phyllodes Tumors: Based on 20-year Real-world Data From China

Role: lead

NCT07631611Completed

Organ-Specific Differences in Immunotherapy Response Among Metastatic Cancer Patients

Role: collaborator

NCT07630103Phase 2Not Yet Recruiting

Efficacy and Safety of Trastuzumab Rezetecan or Trastuzumab Deruxtecan in Advanced Breast Cancer

Role: lead

NCT06511726Phase 2Active Not Recruiting

Induction Chemotherapy Plus Cadonilimab for Locally Advanced Cervical Cancer

Role: lead

NCT06339619Phase 2Recruiting

Combination Immunotherapy of Adebrelimab With Apatinib and Tegafur, Gimeracil and Oteracil Potassium Capsules for Immune Rechallenge Therapy in Esophageal Squamous Cell Carcinoma

Role: lead

NCT06909643Completed

Development and Validation of a Multimodal Fusion Artificial Intelligence Model for Predicting the Efficacy of Neoadjuvant Treatment of Bladder Cancer

Role: lead

NCT07619781Active Not Recruiting

Research on the Development and Validation of Personalized Exercise Prescriptions for Breast Cancer Patients Based on Large Language Models

Role: lead

NCT07618390Phase 2Not Yet Recruiting

A Phase ll, Interventional, Single-arm Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib and Fulvestrant in Chinese Patients With PIK3CA-mutant, HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer.

Role: lead

NCT07129148Not ApplicableRecruiting

Mobile Health and Wearable Devices for Diabetes Complication Management

Role: collaborator

NCT07616011Not Yet Recruiting

Artificial Intelligence-Based Early Warning for Distant Metastasis in Malignant Tumors

Role: lead

NCT07606807Phase 3Not Yet Recruiting

rhTNK-tPA for Acute Ischemic Stroke Under Simplified Imaging in the Extended Time Window

Role: lead

NCT06221267Completed

A Registry Study on Rimegepant for the Treatment of Migraine Participants in Guangdong-Hong Kong-Macao Greater Bay Area

Role: lead

NCT07596472Not Yet Recruiting

Ultrasound Monitoring of Clipped Lymph Nodes to Predict Axillary Response After Chemotherapy in Breast Cancer

Role: lead

NCT07595900Phase 1Not Yet Recruiting

Tocilizumab for the Treatment of Refractory Granulomatous Lobular Mastitis

Role: lead

NCT07595770Phase 2Recruiting

Adebrelimab Combined With Neoadjuvant Chemoradiotherapy for Esophageal Squamous Cell Carcinoma

Role: lead

NCT07596433Active Not Recruiting

Tumor-informed MRD for Non-small Cell Lung Cancer

Role: lead

NCT07595796Not ApplicableNot Yet Recruiting

An Exploratory Study on Triple Inhaler Therapy in Patients With Early Lung Function Impairment

Role: lead

NCT07205497Phase 2Active Not Recruiting

QL1706 Plus Neoadjuvant Chemotherapy Followed by Type I Hysterectomy for Locally Advanced Cervical Cancer

Role: lead